Compare Repligen Corporation Common Stock (RGEN) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while iShares 20 Plus Year Treasury Bond ETF trades at $79.86 (market cap $48.65B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 4.4× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| RGEN | TLT | |
|---|---|---|
Market Cap | $11.14B | $48.65B |
Volume | 1,259,263 | 29,149,160 |
Sector | Health | Fixed Income |
52-Week High | $194.57 | $92.06 |
52-Week Low | $102.87 | $77.11 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $78.89, up 1.08% on the day but remains in a prolonged downtrend, having fallen 46% over five years. Technical indicators are bearish overall, with moving averages and oscillators signaling selling pressure. The fund continues to face headwinds from rising Treasury yields, which recently hit multi-decade highs, though recent PCE data provided some relief.
The outlook for TLT hinges on the direction of long-term interest rates. While current yields near 5.3% offer attractive income, further rate increases could pressure prices lower. Key risks include persistent inflation and Fed policy uncertainty. Investors should weigh high yield against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
